Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Cyclophosphamide and Alemtuzumab In Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT03132584
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 57
- Registration Number
- NCT03077542
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Monica Bhatia
- Target Recruit Count
- 24
- Registration Number
- NCT02867800
- Locations
- 🇺🇸
North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 138
- Registration Number
- NCT02766465
- Locations
- 🇺🇸
Dana Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Boston University, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, Massachusetts, United States
Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 1
- Registration Number
- NCT02678143
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02653196
- Locations
- 🇺🇸
The Children's Hospital at Montefiore, The Bronx, New York, United States
High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
- Conditions
- Interventions
- First Posted Date
- 2015-12-14
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 45
- Registration Number
- NCT02629120
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2015-08-20
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 20
- Registration Number
- NCT02529839
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 40
- Registration Number
- NCT02497404
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Treatment of Familiar Lymphohistiocytosis
- Conditions
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 29
- Registration Number
- NCT02472054
- Locations
- 🇫🇷
Hôpital Necker-Enfants Malades, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.